Bolt Biotherapeutics, INC

Bolt Biotherapeutics announced the results of its 2026 annual meeting of stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Bolt Biotherapeutics reported Q1 2026 financial results, highlighting ongoing BDC-4182 trials with initial data expected in Q3 2026 and a cash runway into 2027.

Bolt Biotherapeutics announced its fourth quarter and full-year 2025 financial results, highlighting progress in its BDC-4182 clinical trial with initial data expected in Q3 2026 and a cash runway into 2027.

Bolt Biotherapeutics announced its third quarter 2025 financial results and provided a business update, including an expected cash runway into 2027 and initial BDC-4182 clinical data in Q3 2026.

Bolt Biotherapeutics announced a 50% workforce reduction to extend its cash runway into 2027, alongside a delay in initial BDC-4182 clinical data to Q3 2026.

Bolt Biotherapeutics reported significantly reduced operating and net losses in the second quarter of 2025, driven by expense reductions and the advancement of its BDC-4182 cancer immunotherapy into a Phase 1 clinical study.

Bolt Biotherapeutics reported a net loss of $7.2 million for Q1 2026, a decrease from the prior year, but highlighted substantial doubt about its ability to continue as a going concern.

Bolt Biotherapeutics reported a net loss of $7.1 million for Q3 2025 and announced a new restructuring plan including a 50% workforce reduction to preserve cash.

Bolt Biotherapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses following a strategic restructuring and pipeline prioritization, despite ongoing going concern doubts.

Bolt Biotherapeutics announces its Q1 2025 financial results, highlighting a net loss of $11.0 million and expressing substantial doubt about its ability to continue as a going concern.

Bolt Biotherapeutics announced its Q3 2024 financial results, highlighting a strategic shift towards key programs and a workforce reduction.

Bolt Biotherapeutics announced its second quarter 2024 financial results, highlighting a strategic pipeline prioritization and restructuring plan.

Bolt Biotherapeutics focuses on BDC-3042 and BDC-4182 after discontinuing BDC-1001, reporting a net loss of $63.1 million for 2024.

Bolt Biotherapeutics, a clinical-stage biopharmaceutical company, released its 2023 annual report, highlighting progress in its clinical programs and financial position.

Bolt Biotherapeutics Director Laura Berner acquired stock options for 5,000 shares of common stock.

Bolt Biotherapeutics Director Kathleen LaPorte acquired stock options for 5,000 shares of common stock.

Jakob Dupont, a Director at Bolt Biotherapeutics, acquired 5,000 stock options with an exercise price of $4.43.

Bolt Biotherapeutics Director Brian O'Callaghan was granted stock options for 5,000 shares.

Nicole Onetto, a Director at Bolt Biotherapeutics, Inc., acquired 5,000 stock options with an exercise price of $4.43.

Bolt Biotherapeutics' President, CEO, and CFO, William P. Quinn, reported an acquisition of common stock and a grant of 20,000 employee stock options.

Bolt Biotherapeutics announces its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, with key proposals including director elections and auditor ratification.

Bolt Biotherapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 27, 2025, to vote on director elections, auditor ratification, and a proposed reverse stock split.

Bolt Biotherapeutics is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.

Bolt Biotherapeutics disclosed a strategic pipeline prioritization and restructuring, leading to changes in its Board and executive leadership, including the departure of the CEO and CMO.

Bolt Biotherapeutics will hold its annual stockholders meeting on June 12, 2024, to vote on the election of directors and the ratification of its independent auditor.

Bolt Biotherapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the selection of its independent accounting firm.

A group of investment entities, including Nan Fung Group and Pivotal bioVenture Partners, have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to below the 5% threshold.

Several Vivo Capital entities have reduced their beneficial ownership in Bolt Biotherapeutics, with some now holding 0% of common stock.

Tang Capital Management and affiliated entities have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to 3.5% of outstanding common stock.

Tang Capital Management and its affiliates have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to 3.5% of common stock.

Tang Capital Management and affiliates report an 8.7% beneficial ownership stake in Bolt Biotherapeutics, Inc. following a recent reverse stock split.

Tang Capital Management, LLC and Kevin Tang, along with affiliated entities, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 9.9% in Bolt Biotherapeutics, Inc.'s common stock.